B J. van der Mast

Down-regulated donor-specific T-cell reactivity during successful tapering of immunosuppression after kidney transplantation

Stable cadaveric renal transplant patients were routinely converted from cyclosporin A (CsA) to either azathioprine (AZA) or mycophenolate mofetil (MMF) 1 year after transplantation to reduce the side effects of long‐term immunosuppressive therapy. Thereafter, the AZA and MMF dose was gradually tapered to 50% at 2 years after transplantation. We questioned whether a reduction of immunosuppressive treatment results in a rise of donor‐specific T‐cell reactivity. Before transplantation (no immunosuppression), 1 year (high dose immunosuppression) and 2 years (low dose immunosuppression) after transplantation, the T‐cell reactivity of peripheral blood mononuclear cells (PBMC) against donor and third‐party spleen cells was tested in mixed lymphocyte cultures (MLC) and against tetanus toxoid (TET) to test the general immune response. We also measured the frequency of donor and third‐party reactive helper (HTLpf) and cytotoxic (CTLpf) T‐lymphocyte precursors in a limiting dilution assay. Donor‐specific responses, calculated by relative responses (RR = donor/third‐party reactivity), were determined. Comparing responses after transplantation during high dose immunosuppression with responses before transplantation (no immmunosuppression), the donor‐specific MLC‐RR (P = 0·04), HTLp‐RR (P = 0·04) and CTLp‐RR (P = 0·09) decreased, while the TET‐reactivity did not change. Comparing the responses during low dose with high dose immunosuppression, no donor‐ specific differences were found in the MLC‐RR, HTLp‐RR and CTLp‐RR, although TET‐reactivity increased considerably (P = 0·0005). We observed a reduction in donor‐specific T‐cell reactivity in stable patients after renal transplantation during in vivo high dose immunosuppression. Tapering of the immunosuppressive load had no rebound effect on the donor‐specific reactivity, while it allowed recovery of the response to nominal antigens.

DIFFERENTIAL EFFECT OF CALCINEURIN INHIBITORS, ANTI-CD25 ANTIBODIES AND RAPAMYCIN ON THE INDUCTION OF FOXP3 IN HUMAN T-CELLS IN VIVO AND IN VITRO

BACKGROUND The transcription factor FOXP3 has been identified as the molecule associated with the regulatory function of CD25+ T cells. METHODS To understand the biology of FOXP3+ T cells in allogeneic reactions, we measured FOXP3 mRNA expression levels in allostimulated CD25 cells and CD25 cells and in peripheral blood mononuclear cells (PBMC). The effect of immunosuppressive drugs on FOXP3 expression was studied in mixed lymphocyte reactions (MLR) in the presence and absence of calcineurin inhibitors (CNI), alphaCD25 mAb, and Rapamycin (Rapa), and analyzed in biopsies from cardiac allograft recipients during acute rejection by quantitative (Q)-PCR. RESULTS FOXP3 mRNA expression was restricted to the CD25 population that inhibited the proliferation of allostimulated CD25 cells. In the MLR FOXP3 was readily induced after allostimulation. Kinetic examination of the MLR showed a 10-20-fold higher FOXP3 mRNA expression level after 5 days of culture. The CNI Cyclosporin and Tacrolimus, and alphaCD25 mAb inhibited in vitro induced FOXP3 gene transcription (range 70%-90%), whereas Rapa did not inhibit the induction. After clinical heart transplantation the highest FOXP3 mRNA expression levels were measured in biopsies during acute rejection (P=0.03). CONCLUSIONS The high FOXP3 mRNA levels during allogeneic responses in vivo and in vitro suggests that regulatory activities of CD25 T cells or the generation of these cells is an intrinsic part of activation. CNI and alphaCD25 mAb in contrast to Rapa, did interfere with this immunosuppressive counter-mechanism and as a result might have an inhibitory effect to tolerance induction after transplantation.